# Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

> **NCT03197506** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Mayo Clinic** · enrollment: 52 (actual)

## Conditions studied

- Glioblastoma
- Gliosarcoma
- Supratentorial Glioblastoma

## Interventions

- **RADIATION:** External Beam Radiation Therapy
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pembrolizumab
- **RADIATION:** Radiation Therapy
- **DRUG:** Temozolomide
- **PROCEDURE:** Therapeutic Conventional Surgery

## Key facts

- **NCT ID:** NCT03197506
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-01-15
- **Primary completion:** 2024-07-16
- **Final completion:** 2028-06-06
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03197506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03197506, "Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03197506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*